Related Experiment Videos

How promising is hematopoetic stem cell transplantation in multiple sclerosis?

Reinhard Hohlfeld

Journal of Neurology

|September 21, 2002

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years.

Multiple sclerosis and related disorders·2026

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026

Ponesimod as add-on treatment in patients with active relapsing multiple sclerosis under dimethyl fumarate (POINT): A phase 3, randomized, placebo-controlled clinical trial.

Multiple sclerosis and related disorders·2025

Multiple sclerosis and gut microbiota: Lachnospiraceae from the ileum of MS twins trigger MS-like disease in germfree transgenic mice-An unbiased functional study.

Proceedings of the National Academy of Sciences of the United States of America·2025

Twin study identifies early immunological and metabolic dysregulation of CD8+ T cells in multiple sclerosis.

Science immunology·2024

Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis.

The Journal of experimental medicine·2022

See all related articles